GSK reports 62% response rate for Mo‑Rez in platinum‑resistant ovarian cancer
GSK disclosed updated Phase I BEHOLD‑1 data for its B7‑H4‑targeted ADC mo‑rez, showing a 62% confirmed objective response rate in patients with platinum‑resistant ovarian cancer. Median duration of response was 12.2 months and median progression‑free survival was 11.1 months. The company said it will accelerate development with five pivotal Phase III trials now underway, and the results will be presented at ESMO 2026.
Why it matters
The strong efficacy signals could enhance GSK's oncology pipeline and support the commercial potential of the mo‑rez licence, which GSK says may be worth up to $3.28 billion including upfront fees of $270 million. The accelerated Phase III programme may create future revenue streams if the drug receives regulatory approval.
Key facts
- 1Objective response rate was 62% in the BEHOLD‑1 Phase I trial. pharmaphorum.com
- 2Median duration of response was 12.2 months. pharmaphorum.com
- 3Median progression‑free survival was 11.1 months. pharmaphorum.com
- 4Grade ≥ 3 treatment‑related adverse events occurred in 71% of patients, with 2% discontinuations. pharmaphorum.com
- 5The mo‑rez licence from Hansoh could be worth up to $3.28 billion, including $270 million upfront fees. pharmaphorum.com
- 6Five pivotal Phase III trials are now ongoing across gynaecological cancers. directorstalkinterviews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.